DK2018164T3 - Anvendelse af kombinationspræparater omfattende antimykotika - Google Patents
Anvendelse af kombinationspræparater omfattende antimykotika Download PDFInfo
- Publication number
- DK2018164T3 DK2018164T3 DK07718439.8T DK07718439T DK2018164T3 DK 2018164 T3 DK2018164 T3 DK 2018164T3 DK 07718439 T DK07718439 T DK 07718439T DK 2018164 T3 DK2018164 T3 DK 2018164T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapy
- combination
- vaginal
- treatment
- adhesion
- Prior art date
Links
- 239000002543 antimycotic Substances 0.000 title claims description 15
- 230000001857 anti-mycotic effect Effects 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title description 19
- 238000011282 treatment Methods 0.000 claims description 38
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical group ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 27
- 229960004022 clotrimazole Drugs 0.000 claims description 24
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 23
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 23
- 201000004624 Dermatitis Diseases 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 12
- 239000002674 ointment Substances 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 12
- 229960001259 diclofenac Drugs 0.000 claims description 11
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 11
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 10
- 208000010668 atopic eczema Diseases 0.000 claims description 10
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 10
- 229960003464 mefenamic acid Drugs 0.000 claims description 10
- 229940000425 combination drug Drugs 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 9
- 229960002509 miconazole Drugs 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 206010050346 Oropharyngeal candidiasis Diseases 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims description 6
- 229940044977 vaginal tablet Drugs 0.000 claims description 5
- 239000000003 vaginal tablet Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000006216 vaginal suppository Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000007936 buccal or sublingual tablet Substances 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 229940120293 vaginal suppository Drugs 0.000 claims description 3
- 229940044953 vaginal ring Drugs 0.000 claims description 2
- 239000006213 vaginal ring Substances 0.000 claims description 2
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 claims 2
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 claims 2
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 claims 2
- 241001282110 Pagrus major Species 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 49
- 230000000694 effects Effects 0.000 description 28
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 26
- 208000007027 Oral Candidiasis Diseases 0.000 description 25
- 239000000126 substance Substances 0.000 description 23
- 239000003429 antifungal agent Substances 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 244000052769 pathogen Species 0.000 description 19
- 241000233866 Fungi Species 0.000 description 18
- 208000031888 Mycoses Diseases 0.000 description 18
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 16
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 16
- 230000001717 pathogenic effect Effects 0.000 description 16
- 206010007134 Candida infections Diseases 0.000 description 15
- 201000003984 candidiasis Diseases 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 241000287411 Turdidae Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 208000010484 vulvovaginitis Diseases 0.000 description 14
- 210000002889 endothelial cell Anatomy 0.000 description 13
- 210000002919 epithelial cell Anatomy 0.000 description 12
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 12
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 11
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 238000009097 single-agent therapy Methods 0.000 description 10
- 229940114079 arachidonic acid Drugs 0.000 description 9
- 235000021342 arachidonic acid Nutrition 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000021164 cell adhesion Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 7
- 229940111134 coxibs Drugs 0.000 description 7
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 210000003905 vulva Anatomy 0.000 description 7
- 238000012404 In vitro experiment Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000003756 cervix mucus Anatomy 0.000 description 6
- 229960004884 fluconazole Drugs 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 238000009121 systemic therapy Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 206010046901 vaginal discharge Diseases 0.000 description 6
- 206010017533 Fungal infection Diseases 0.000 description 5
- 238000013475 authorization Methods 0.000 description 5
- 208000024386 fungal infectious disease Diseases 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010046914 Vaginal infection Diseases 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229960000988 nystatin Drugs 0.000 description 4
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001313288 Labia Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 201000008100 Vaginitis Diseases 0.000 description 3
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 229960001123 epoprostenol Drugs 0.000 description 3
- 238000012153 long-term therapy Methods 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000333 benzydamine Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 230000008756 pathogenetic mechanism Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108010007389 Trefoil Factors Proteins 0.000 description 1
- 102000007641 Trefoil Factors Human genes 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 208000005035 cutaneous candidiasis Diseases 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000018612 quorum sensing Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- -1 tincture Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (2)
1. : Kombinationslægemiddel indeholdende - et antimykotisk aktivstof, hvor det antimykotiske aktivstof er clotrimazol eller miconazol, og - et non-steroidt antiinflammatorisk middel (NSAID) med en tilstrækkelig COX1-inhibering, defineret ved udelukkelse af forbindelser med et COX1/COX-2-forhold (IC50, microM) på > 20, hvor nævnte NSAID er diclofenac eller mefenaminsyre, til anvendelse til topisk behandling af candi-damykoser, der er valgt blandt vulvovaginal candidiasis, oropharyngeal candidiasis (svamp i munden), bledermatitis (rød hale) og intertriginøs eksem, hvor kombinationslægemidlet er en salve, en creme, en vaginal stikpille, en vaginal, bukkal eller sublingual tablet, et pulver eller en aerosol.
2. : Kombinationslægemiddel til anvendelse ifølge krav 1, kendetegnet ved, at kombinationslægemidlet er tilvejebragt på en inert bærer, især på en vaginalring, et pessar eller en tampon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT8262006 | 2006-05-12 | ||
| PCT/AT2007/000227 WO2007131253A2 (de) | 2006-05-12 | 2007-05-10 | Verwendung von kombinationspräparaten, umfassend antimykotika |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2018164T3 true DK2018164T3 (da) | 2017-06-12 |
Family
ID=37903545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07718439.8T DK2018164T3 (da) | 2006-05-12 | 2007-05-10 | Anvendelse af kombinationspræparater omfattende antimykotika |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8552042B2 (da) |
| EP (2) | EP3192507B1 (da) |
| JP (1) | JP2009536926A (da) |
| CN (1) | CN101484162A (da) |
| AU (1) | AU2007250502B2 (da) |
| CA (1) | CA2651726C (da) |
| CY (1) | CY1119094T1 (da) |
| DK (1) | DK2018164T3 (da) |
| ES (1) | ES2627268T3 (da) |
| HR (1) | HRP20170793T1 (da) |
| HU (1) | HUE033499T2 (da) |
| LT (1) | LT2018164T (da) |
| NO (2) | NO342103B1 (da) |
| PL (1) | PL2018164T3 (da) |
| PT (1) | PT2018164T (da) |
| RS (1) | RS56044B1 (da) |
| RU (1) | RU2008148977A (da) |
| SI (1) | SI2018164T1 (da) |
| WO (1) | WO2007131253A2 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI23311A (sl) * | 2010-03-19 | 2011-09-30 | Kemijski inštitut | Farmacevtska kombinacija acetilsalicilne kisline in protiglivne substance za uničevanje ali inhibicijo rasti in replikacije gliv |
| CN102210649A (zh) * | 2010-04-09 | 2011-10-12 | 上海医药科技发展有限公司 | 一种两性霉素b乳膏及其制备方法 |
| FR2993179B1 (fr) * | 2012-07-13 | 2016-01-08 | Lesaffre & Cie | Levure saccharomyces cerevisiae pour prevenir et/ou traiter les mycoses vaginales |
| CN103044408A (zh) * | 2013-01-21 | 2013-04-17 | 万礼 | 在治疗恶性肿瘤时应用的伊曲康唑或其盐及其组合物 |
| US8883747B1 (en) * | 2013-10-09 | 2014-11-11 | Craig W. Carver | Topical antifungal compositions and methods of use thereof |
| JP6714597B2 (ja) | 2015-01-13 | 2020-06-24 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | 真菌症（ｍｙｃｏｓｉｓ）の治療のための医薬組成物 |
| CN104920360B (zh) * | 2015-06-18 | 2017-04-12 | 青岛农业大学 | 丁苯羟酸在制备用于防治由植物病原菌引起的植物病害的杀菌剂中的用途 |
| RS64869B1 (sr) | 2017-11-14 | 2023-12-29 | Profem Gmbh | Emulzije za lečenje vaginalnih infekcija |
| EP3482743A1 (de) | 2017-11-14 | 2019-05-15 | ProFem GmbH | Emulsionen zur behandlung von scheideninfektionen |
| EP3482744A1 (de) | 2017-11-14 | 2019-05-15 | ProFem GmbH | Emulsionen zur topischen behandlung urogenitaler und dermaler infektionen |
| FR3089788B1 (fr) * | 2018-12-17 | 2020-12-18 | Lesaffre & Cie | Souche de levure Saccharomyces cerevisiae pour le traitement et/ou la prévention de candidoses oropharyngées |
| US20250302821A1 (en) * | 2022-05-12 | 2025-10-02 | St. Jude Children's Research Hospital, Inc. | Synergistic antifungal composition and method |
| WO2024187210A1 (de) | 2023-03-15 | 2024-09-19 | Profem Gmbh | Kombinationsarzneimittel zur behandlung und reduktion der rückfallraten vaginaler mykosen |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6471823A (en) * | 1987-09-12 | 1989-03-16 | Rohto Pharma | Sustained remedy for vaginal candidiasis |
| US5087620A (en) * | 1990-05-17 | 1992-02-11 | Bristol-Myers Squibb Co. | Controlled dermal penetration enhancement using imidazoles |
| ES2079994B1 (es) | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
| CA2177683C (en) * | 1993-12-23 | 1999-12-28 | George Endel Deckner | Tissue moisturizing and antimicrobial compositions |
| US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| WO2000048633A1 (en) * | 1999-02-19 | 2000-08-24 | Ligocyte Pharmaceuticals, Inc. | Antibodies against hydrophobic proteins that are protective against candidiasis |
| WO2000059527A1 (en) | 1999-03-24 | 2000-10-12 | Zengen, Inc. | Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone |
| GB0108082D0 (en) | 2001-03-30 | 2001-05-23 | Novartis Consumer Health Sa | Topical composition |
| US20030181384A1 (en) | 2001-09-06 | 2003-09-25 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| US20040142910A1 (en) * | 2002-10-21 | 2004-07-22 | Aegis Biosciences Llc | Sulfonated styrene copolymers for medical uses |
| AU2003293529A1 (en) * | 2002-12-16 | 2004-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| EP1637132B1 (en) | 2003-06-25 | 2010-10-06 | Hisamitsu Pharmaceutical Co., Inc. | External preparation for athlete´s foot treatment |
| WO2005009342A2 (en) | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| ES2237298B1 (es) | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
| CN1988887A (zh) * | 2004-05-28 | 2007-06-27 | 先灵公司 | 包含泊沙康唑的注射用药物混悬剂 |
-
2007
- 2007-05-10 CA CA2651726A patent/CA2651726C/en active Active
- 2007-05-10 RU RU2008148977/15A patent/RU2008148977A/ru not_active Application Discontinuation
- 2007-05-10 WO PCT/AT2007/000227 patent/WO2007131253A2/de active Application Filing
- 2007-05-10 RS RS20170559A patent/RS56044B1/sr unknown
- 2007-05-10 PT PT77184398T patent/PT2018164T/pt unknown
- 2007-05-10 HR HRP20170793TT patent/HRP20170793T1/hr unknown
- 2007-05-10 EP EP17158393.3A patent/EP3192507B1/de active Active
- 2007-05-10 CN CNA200780025026XA patent/CN101484162A/zh active Pending
- 2007-05-10 DK DK07718439.8T patent/DK2018164T3/da active
- 2007-05-10 LT LTEP07718439.8T patent/LT2018164T/lt unknown
- 2007-05-10 ES ES07718439.8T patent/ES2627268T3/es active Active
- 2007-05-10 EP EP07718439.8A patent/EP2018164B1/de active Active
- 2007-05-10 JP JP2009508042A patent/JP2009536926A/ja active Pending
- 2007-05-10 US US12/300,578 patent/US8552042B2/en active Active
- 2007-05-10 AU AU2007250502A patent/AU2007250502B2/en active Active
- 2007-05-10 SI SI200731935A patent/SI2018164T1/sl unknown
- 2007-05-10 PL PL07718439T patent/PL2018164T3/pl unknown
- 2007-05-10 HU HUE07718439A patent/HUE033499T2/en unknown
-
2008
- 2008-12-11 NO NO20085181A patent/NO342103B1/no unknown
-
2013
- 2013-10-02 US US14/044,532 patent/US8815925B2/en active Active
-
2017
- 2017-05-30 CY CY20171100556T patent/CY1119094T1/el unknown
-
2018
- 2018-01-18 NO NO20180083A patent/NO345064B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2018164T1 (sl) | 2017-07-31 |
| PT2018164T (pt) | 2017-06-12 |
| PL2018164T3 (pl) | 2017-08-31 |
| NO345064B1 (no) | 2020-09-14 |
| WO2007131253A3 (de) | 2008-11-27 |
| RS56044B1 (sr) | 2017-09-29 |
| ES2627268T3 (es) | 2017-07-27 |
| NO342103B1 (no) | 2018-03-26 |
| RU2008148977A (ru) | 2010-06-20 |
| CA2651726C (en) | 2015-12-15 |
| LT2018164T (lt) | 2017-07-10 |
| NO20085181L (no) | 2009-02-10 |
| EP2018164A2 (de) | 2009-01-28 |
| HUE033499T2 (en) | 2017-12-28 |
| AU2007250502A1 (en) | 2007-11-22 |
| EP3192507A1 (de) | 2017-07-19 |
| EP3192507B1 (de) | 2020-07-08 |
| US20090208558A1 (en) | 2009-08-20 |
| NO20180083A1 (no) | 2009-02-10 |
| CY1119094T1 (el) | 2018-01-10 |
| EP2018164B1 (de) | 2017-03-01 |
| US20140030312A1 (en) | 2014-01-30 |
| US8815925B2 (en) | 2014-08-26 |
| CN101484162A (zh) | 2009-07-15 |
| JP2009536926A (ja) | 2009-10-22 |
| HRP20170793T1 (hr) | 2017-10-06 |
| US8552042B2 (en) | 2013-10-08 |
| AU2007250502B2 (en) | 2013-11-28 |
| CA2651726A1 (en) | 2007-11-22 |
| WO2007131253A2 (de) | 2007-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2018164T3 (da) | Anvendelse af kombinationspræparater omfattende antimykotika | |
| US20030017207A1 (en) | Compositions and methods for treating vulvovaginitis and vaginosis | |
| AU2010212634A1 (en) | Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases | |
| KR101100713B1 (ko) | 아스코르브산을 포함하는 진균성 중복감염들 및 진균성재발들의 치료용 약학적 조성물들 | |
| AU2017261517B2 (en) | Use of combination preparations, comprising antimycotics | |
| Botter | Further experiences with miconazole nitrate, a broad‐spectrum antimycotic with antibacterial activity | |
| RU2293558C2 (ru) | Средство для лечения гинекологических и проктологических заболеваний | |
| AU2013254945A1 (en) | Use of combination preparations, comprising antimycotics | |
| CA2553646C (en) | Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage | |
| EP4149426B1 (fr) | Comprime mucoadhesif pour le traitement des infections fongiques oropharyngees | |
| CN120437267A (zh) | 沙丁鱼肽组合物在制备防治唇炎的药物中的新用途 | |
| MXPA06008279A (en) | Fluconazole-tinidazole combination for the treatment of vaginal infections, composition thereof and preparation and use of same | |
| EA048135B1 (ru) | Применение сепиаптерина и его метаболитов для лечения радиационного облучения | |
| OLTEAN | MANAGEMENT OF MUCOCUTANEOUS CANDIDIASIS | |
| TW201124138A (en) | Imidazole-4-carboxylic acid for use in treating a disease related to extracellular reactive oxygen species | |
| AU2002309593A1 (en) | Composition comprising antifungal agents for treating vulvovaginitis and vaginosis | |
| HK1075604A (en) | Pharmaceutical compositions comprising ascorbic acid or the treatment of fungal superinfections and fungal recurrences | |
| HK1092693B (en) | Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences |